HSBC Holdings
PACB icon

HSBC Holdings’s Pacific Biosciences PACB Stock Holding History

HSBC Holdings’s Portfolio PACB Stock Details PACB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$463K Buy
280,306
+31,829
+13% +$46.3K ﹤0.01% 2317
2026
Q1 		$327K Buy
248,477
+195,769
+371% +$350K ﹤0.01% 2418
2025
Q4 		$97.8K Buy
+52,708
New +$101K ﹤0.01% 2794
2025
Q3 		– Sell
-15,830
Closed -$20.3K – 3031
2025
Q2 		$20.3K Sell
15,830
-70,771
-82% -$81.7K ﹤0.01% 2977
2025
Q1 		$100K Sell
86,601
-208
-0.2% -$319 ﹤0.01% 2807
2024
Q4 		$154K Buy
86,809
+8,106
+10% +$15.8K ﹤0.01% 2786
2024
Q3 		$137K Sell
78,703
-419
-0.5% -$688 ﹤0.01% 2730
2024
Q2 		$106K Buy
79,122
+32,899
+71% +$66.4K ﹤0.01% 2719
2024
Q1 		$173K Sell
46,223
-30,757
-40% -$180K ﹤0.01% 2726
2023
Q4 		$759K Buy
76,980
+47,600
+162% +$389K ﹤0.01% 1892
2023
Q3 		$242K Buy
+29,380
New +$336K ﹤0.01% 2328
2022
Q3 		– Sell
-95,454
Closed -$422K – 3177
2022
Q2 		$422K Sell
95,454
-1,499
-2% -$9.11K ﹤0.01% 2434
2022
Q1 		$883K Buy
96,953
+53,919
+125% +$621K ﹤0.01% 2033
2021
Q4 		$880K Hold
43,034
– – ﹤0.01% 2124
2021
Q3 		$1.1M Buy
43,034
+32,639
+314% +$967K ﹤0.01% 1827
2021
Q2 		$364K Buy
+10,395
New +$302K ﹤0.01% 2393
2021
Q1 		– Sell
-15,567
Closed -$405K – 3023
2020
Q4 		$405K Buy
+15,567
New +$265K ﹤0.01% 2342
2020
Q3 		– Sell
-42,672
Closed -$147K – 2815
2020
Q2 		$147K Buy
42,672
+16,837
+65% +$57.3K ﹤0.01% 2449
2020
Q1 		$79K Buy
25,835
+12,753
+97% +$52.2K ﹤0.01% 2503
2019
Q4 		$69K Sell
13,082
-882,204
-99% -$4.48M ﹤0.01% 2957
2019
Q3 		$4.62M Buy
895,286
+29,328
+3% +$164K 0.01% 1225
2019
Q2 		$5.24M Buy
+865,958
New +$6.07M 0.01% 1126
2017
Q1 		– Sell
-13,836
Closed -$53K – 2459
2016
Q4 		$53K Buy
+13,836
New +$101K ﹤0.01% 2667

Other funds holding PACB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HSBC Holdings's PACB Position: Q2 2026 in Review

HSBC Holdings increased its Pacific Biosciences (PACB) stake by 13% in Q2 2026, buying an estimated $46.3K and bringing the position to 280,306 shares worth $463K. The position accounts for ﹤0.01% of the portfolio, ranked #2317.

HSBC Holdings first reported a position in PACB in Q4 2016 and has held it in 23 quarters since. The position peaked at $5.24M in Q2 2019. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

  • HSBC Holdings held 280,306 shares of Pacific Biosciences worth $463K as of Q2 2026.
  • HSBC Holdings bought 31,829 Pacific Biosciences shares in Q2 2026, an estimated $46.3K.
  • Pacific Biosciences made up ﹤0.01% of HSBC Holdings's portfolio in Q2 2026, its #2317 holding.
  • HSBC Holdings first reported a position in Pacific Biosciences in Q4 2016 and has held it in 23 quarters since.
  • HSBC Holdings's Pacific Biosciences position peaked at $5.24M in Q2 2019.
  • 223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on HSBC Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.